echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Development Pharmaceuticals Furitan in the treatment of androgenetic alopecia China Phase II clinical trial reached the primary endpoint

    Development Pharmaceuticals Furitan in the treatment of androgenetic alopecia China Phase II clinical trial reached the primary endpoint

    • Last Update: 2021-09-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 8, Kaifeng Pharmaceutical announced that the China Phase II clinical trial of freitan (tincture) for the treatment of androgenetic alopecia has reached the primary endpoint


    The Phase II clinical trial conducted in China is a multi-center, randomized, double-blind, placebo-controlled clinical study involving 120 subjects in order to evaluate the effectiveness of freitan in the treatment of androgenetic alopecia in adult men.


    The results showed that Freitaen is safe for the treatment of androgenetic alopecia.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.